Impact of fasting on intestinal stem cells and cancer

点击翻译按钮获取中文摘要

PROJECT SUMMARY Fasting regimens can increase lifespan, improve health or both in diverse species including mammals. Fasting also has an emerging role in inhibiting tumor growth, yet little is known about how it impacts tumor initiation or how fasting-imposed metabolism can be therapeutically exploited to treat established tumors. Given that adult stem cells coordinate tissue adaptation and drive tumorigenesis, understanding the mechanism(s) that mediate their response to fasting has important implications for enhancing tissue repair after injury or aging where stem cell function declines, and may provide new therapeutic inroads for cancer. In the mouse intestine, where LGR5+ intestinal stem cells (ISCs) drive the rapid renewal of the intestinal lining, we showed that fasting augments ISC function by inducing a peroxisome proliferator-activated receptor delta (PPARd) driven fatty acid oxidation (FAO) program, which breaks down free fatty acids into acetyl-CoA units. This work raises the critical question of how fasting functions through the FAO pathway to regulate intestinal stemness. We hypothesize that beta-hydroxybutyrate (βOHB), a ketone body and biosynthetic product of FAO generated acetyl- CoA, functions as a signaling metabolite and energetic substrate that mediates the ISC fasting response. In support of this idea, we recently found that the LGR5+ ISCs strongly express enzymes of the ketogenic pathway that produce βOHB, including its rate-limiting enzyme HMGCS2 (3-hydroxy-3- methylglutaryl-CoA synthetase 2), compared to non-stem cell populations and that fasting strongly elevates HMGCS2 and βOHB levels in ISCs. HMGCS2 loss in the small intestine reduces βOHB levels in LGR5+ ISCs and skews their differentiation towards secretory cell fates, which we showed can be rescued by exogenous βOHB and class I histone deacetylases (HDACs) inhibitor treatment. Mechanistically, βOHB acts as a signaling metabolite to reinforce the NOTCH program in ISCs by inhibiting HDAC-mediated transcriptional repression. Dynamic control of βOHB levels in ISCs, therefore, could enable the rapid adaptation of the intestine to diverse physiological states like fasting. Many important questions that form the basis of our aims remain regarding the role ketone bodies as effectors of the fasting response in ISCs such as understanding the in vivo signaling (Aim 1) and energetic (Aim 2) roles of βOHB in this process. Another critical question is to decipher how the fasting-induced FAO program in ISCs influences tumor initiation and progression (Aim 3). !